JL Mag Rare-Earth (300748.SZ) plans to implement a green intelligent manufacturing project for the annual production of 20,000 tons of high-performance rare-earth permanent magnet materials, with an investment of 1.05 billion yuan.
Jinli Permanent Magnet (300748.SZ) Announcement, the company plans to establish a wholly-owned subsidiary Jinli Permanent Magnet (Baotou) Technology Co., Ltd.
Announcement of Jl Mag Rare-Earth (300748.SZ): The company plans to invest in the construction of the "annual production of 20,000 tons of high-performance rare earth permanent magnet material green intelligent manufacturing project" through its wholly-owned subsidiary Jl Mag Rare-Earth (Baotou) Technology Co., Ltd. (referred to as "Jinli Baotou Company"). The total planned investment for the project is 1.05 billion yuan, with a construction period of 2 years. After completion, the company will have an annual production capacity of 60,000 tons of high-performance rare earth permanent magnet materials.
The announcement stated that the construction of this project is an important measure for the company to further consolidate its group production capacity, improve its industrial layout, expand the company's business scale, and meet customers' order demands in the field of new energy vehicles, frequency conversion air conditioning, and Siasun Robot & Automation in the new energy and energy conservation and environmental protection sectors.
Related Articles

On April 10, Billion Industries Holdings Limited (stock code 02299) spent 39,200 Hong Kong dollars to repurchase 8,000 shares.

Yue Yuen Industries (00551) total comprehensive operating income for the first three months decreased by 2.2% year-on-year to 1.985 billion US dollars.

Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-5765 tablets have obtained the drug clinical trial approval letter.
On April 10, Billion Industries Holdings Limited (stock code 02299) spent 39,200 Hong Kong dollars to repurchase 8,000 shares.

Yue Yuen Industries (00551) total comprehensive operating income for the first three months decreased by 2.2% year-on-year to 1.985 billion US dollars.

Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-5765 tablets have obtained the drug clinical trial approval letter.

RECOMMEND





